ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
Webcast on January 23 at 1:00 p.m. PT/4:00 p.m. ET will review…
Empowering Youth: Students Learn About Cancer Detection, Treatment, and Hope
Manipal Hospital Old Airport Road Raises Cancer Awareness with 'Breaking Barriers, Building…
Investigational Epcoritamab (DuoBody CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
Media ReleaseCOPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE® CLL-1…
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate…
A2 Bio Highlights Progress of Tmod CAR T-Cell Clinical Programs During 2024 Annual Meeting of the Society for Immunotherapy of Cancer
Oral presentation provides update on enhancements to improve participant diversity and enrollment…
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
Data presented in an oral session at the Society for Immunotherapy of…
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
November 09, 2024 13:00 ET | Source: Replimune Group Inc Oral presentation…